HeartBeam (BEAT) Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Net Cash Used in Operating Activities: $3.3 million for Q2 2026, a 7% decrease from Q1 2026 and a 3% decrease year-over-year.

Net Loss: $5 million for the quarter, with underlying loss adjusted to approximately $4.1 million after accounting for one-time items related to leadership transition. This represents a 12% decrease compared to the prior quarter and a 17% decrease year-over-year.

Cash Position: As of June 30, 2026, cash equivalents and restricted cash totaled $8.8 million, extending the cash runway into 2027.

Operating Cash Flow Guidance: Expected to step down to below $2.5 million per quarter by Q4 2026.

2Strategic Updates and Business Highlights

Product Development: Completed the working prototype for the 12-lead EKG patch and the credit card-sized HeartBeam System, which are critical for heart attack detection.

Clinical Studies: Advanced heart attack detection initiatives with successful pilot studies, including the ALIGN-ACS study, which enrolled 134 patients in less than four months, and the HEADSTART-ACS study in Indonesia, which is over 50% enrolled.

Regulatory Progress: Submitted a pre-submission to the FDA for heart attack detection, with expectations for a pivotal trial to begin by year-end.

Commercial Launch: Initial rollout in concierge practices is underway, with positive feedback from physicians and patients. The company aims to integrate HeartBeam technology into patient workflows effectively.

3Forward Guidance and Outlook

Revenue Generation: The company anticipates generating revenue from the initial commercial launch in the second half of 2026 and expects to see increased order flow as the integration into concierge practices matures.

Market Potential: Targeting a market of approximately 1.9 million patients in concierge services, with expectations that around 20% may be at-risk cardiac patients.

Break-even Point: Estimated at around 30,000 patients, with the potential to achieve this through the current agreements and ongoing commercial efforts.

4Bad News, Challenges, or Points of Concern

Leadership Transition Costs: One-time costs associated with the leadership transition impacted net loss figures.

Regulatory Risks: While the FDA submission is a positive step, the outcome is uncertain, and any delays or complications could impact timelines for commercialization.

Market Competition: The company faces competition in the cardiac monitoring space, and the success of its technology will depend on effective differentiation and adoption in a crowded market.

5Notable Q&A Insights

Licensing Strategy: Clarified that the focus is on partnerships with integrated systems rather than traditional licensing of technology, with potential for licensing discussions post-trial in Indonesia.

International Expansion: Currently prioritizing the Indonesian market for global expansion, with plans to assess other international opportunities based on outcomes there.

Patient Onboarding: The company is gathering metrics on patient onboarding in concierge practices, with expectations of significant growth in 2027 based on initial positive feedback and integration strategies. Overall, HeartBeam is positioned for growth with promising technology and strategic initiatives, although it faces challenges related to regulatory approval and market competition.